Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: Results of the virahep-C study

American Journal of Gastroenterology

Volumn 104, Issue 12, 2009, Pages 2949-2958

  Evon, Donna M ^a   Ramcharran, Darmendra ^b,c   Belle, Steven H ^b   Terrault, Norah A ^d   Fontana, Robert J ^e   Fried, Michael W ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c Via Research LLC ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; FEMALE; HEPATITIS C; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOCIAL SUPPORT; SUICIDE ATTEMPT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON ALFA-2A; MALE; MULTICENTER STUDIES AS TOPIC; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; UNITED STATES;

EID: 72949113021     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.528     Document Type: Article

References (50)

1. SeeffLB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C:2002. Hepatology 2002;36 (5 Suppl 1): S1-2.
2. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
3. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
4. Conjeevaram HS, Fried MW, Jeffers LJ et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-477
5. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36 (5 Suppl 1): S237-44.
6. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000;157:867-876
7. Schafer A, Wittchen HU, Seufert J et al. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int J Methods Psychiatr Res 2007;16:186-201.
8. Dieperink E, Ho SB, Thuras P et al. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44:104-112
9. Hauser P, Khosla J, Aurora H et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7:942-947
10. Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000;18:107-116
11. Kraus MR, Schafer A, Faller H et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003;64:708-714
12. Evon DM, Verma A, Simpson K et al. Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre. Aliment Pharmacol Ther 2008;27:1071-1080
13. Zdilar D, Franco-Bronson K, Buchler N et al. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-1211
14. Raison CL, Demetrashvili M, Capuron L et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005;19:105-123
15. Rifai MA, Indest D, Loft is J et al. Psychiatric management of the hepatitis C patient. Curr Treat Options Gastroenterol 2006;9:508-519
16. Raison CL, Broadwell SD, Borisov AS et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005;19:23-27
17. Maddock C, Landau S, Barry K et al. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry 2005;10:332-333
18. Evon DM, Verma A, Dougherty KA et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 2007;52:3251-3258
19. Loft is JM, Hauser P, Rifai MA. The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin. Brain Behav Immun 2005;19:271-272
20. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999;340:1370.
21. Horikawa N, Yamazaki T, Izumi N et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003;25:34-38
22. Kraus MR, Schafer A, Al-Taie O et al. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005;12:96-100.
23. Schaefer M, Schmidt F, Folwaczny C et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37:443-451
24. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med 1991;32:705-714
25. RadloffLS. The CES-D Scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1977;1:385-401.
26. Zich JM, Attkisson CC, Greenfield TK. Screening for depression in primary care clinics: the CES-D and the BDI. Int J Psychiatry Med 1990;20:259-277
27. Thomas JL, Jones GN, Scarinci IC et al. The utility of the CES-D as a depression screening measure among low-income women attending primary care clinics. The Center for Epidemiologic Studies-Depression. Int J Psychiatry Med 2001;31:25-40.
28. Wison Schaeffer JJ, Gil KM, Burchinal M et al. Depression, disease severity, and sickle cell disease. J Behav Med 1999;22:115-126
29. Carnike CLM. Is social desirability associated with symptom distress in organ transplant candidates? Psychol Health Med 1997;2:243-251
30. Putzke JD, Boll TJ, Williams MA et al. Self-report measures among transplant candidates: the impact of evaluative situations. Assessment 2001;8:19-35.
31. Carnike CLM, McCracken LM, Aikens JE. Social desirability, perceived stress, and PACT ratings in lung transplant candidates: a preliminary investigation. J Clin Psychol Med Settings 1996;3:57-67.
32. Valentine AD, Meyers CA, Kling MA et al. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998;25 (1 Suppl 1):39-47.
33. McAndrews MP, Farcnik K, Carlen P et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005;41:801-808
34. Weissenborn K, Krause J, Bokemeyer M et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004;41:845-851
35. Van Thiel DH, Friedlander L, Molloy PJ et al. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995;7:165-168
36. Schaefer M, Hinzpeter A, Mohmand A et al. Hepatitis C treatment in " difficult-to-treat " psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatol 2007;46:991-998
37. Ho SB, Nguyen H, Tetrick LL et al. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001;1:157-164
38. Lindsay KL, Morishima C, Wright EC et al. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008;6:234-241
39. Loft is JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004;82:175-190
40. Maes M, Yirmyia R, Noraberg J et al. The inflammatory & neurodegenerative (I & ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009;24:27-53.
41. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002;5:375-388
42. Berkman LF, Syme SL. Social networks, host resistance, and mortality: a nine-year follow-up study of Alameda County residents. Am J Epidemiol 1979;109:186-204.
43. Seeman TE, Kaplan GA, Knudsen L et al. Social network ties and mortality among the elderly in the Alameda County Study. Am J Epidemiol 1987;126:714-723
44. Uchino BN. Social Support and Health: a Review of Physiological Processes Potentially Underlying Links to Disease Outcomes. J Behavioral Medicine 2006;29:377-387
45. Reblin M, Uchino BN. Social and emotional support and its implication for health. Curr Opin Psychiatry 2008;21:201-205
46. McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity: an investigation in a trial of recombinant á-interferon in hepatitis-B carriers. Lancet 1987;2:1175-1178
47. Carrico AW, Antoni MH, Weaver KE et al. Cognitive-behavioural stress management with HIV-positive homosexual men: mechanisms of sustained reductions in depressive symptoms. Chronic Illn 2005;1:207-215
48. Antoni MH, Wimberly SR, Lechner SC et al. Reduction of cancer-specific thought intrusions and anxiety symptoms with a stress management intervention among women undergoing treatment for breast cancer. Am J Psychiatry 2006;163:1791-1797
49. Beynon S, Soares-Weiser K, Woolacott N et al. Psychosocial interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials. Br J Psychiatry 2008;192:5-11.
50. Smith MC, Holcombe JK, Stullenbarger E. A meta-analysis of intervention effectiveness for symptom management in oncology nursing research. Oncol Nurs Forum 1994;21:1201-9;discussion 1209-1210